Journal of Drugs in Dermatology articles from January 2005

Journal of Drugs in Dermatology archives from January 2005

A letter from the guest editor.
January 1, 2005... One hundred years ago, a walk on the moon was considered a fantasy and the Wright brothers' Kitty Hawk flight was hot news. We have come far since then and the past two decades have been filled with a variety of technological advances...

A dermatologist's response to the American Academy of Pediatrics guidelines on head lice.(LETTERS TO THE EDITOR)(Letter to the Editor)
January 1, 2005... The American Academy of Pediatrics (AAP) allows a small committee of its members to formulate and publish policy statements for the entire specialty. In one of these quorums, a few pediatric delegates recently addressed the subject of head lice...

The potential utility of statin vaginal gels in the prevention of HIV transmission.(LETTERS TO THE EDITOR)(Letter to the Editor)
January 1, 2005... Prevention of HIV transmission when a sexual partner is a known case of HIV disease is a very important anti-HIV preventive measure. Transmigration of HIV-infected mononuclear cells across the genital mucosa is one of the mechanisms of...

Longevity of effects of injectable products for soft-tissue augmentation.
January 1, 2005... Abstract With the growing number of injectable products for soft-tissue augmentation, non-surgical total facial restoration is within reach. Nevertheless, the ideal injectable product has yet to be developed; at present different...

A multicenter, open-label study to assess the safety and efficacy of ciclopirox topical suspension 0.77% in the treatment of diaper dermatitis due to Candida albicans.
January 1, 2005... Abstract Ciclopirox is a broad-spectrum antifungal, antibacterial, and anti-inflammatory agent. This open-label study investigated the safety and efficacy of ciclopirox topical suspension 0.77% in the treatment of diaper dermatitis due to...

Photorejuvenation of facial skin with topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a split-face comparison study.
January 1, 2005... Abstract Background: Photorejuvenation of facial skin has been reported after intense pulsed light (IPL) therapy alone and in conjunction with topical 5-aminolevulinic acid (5-ALA), but no comparative studies between these regimens have...

Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids.
January 1, 2005... Abstract Retinoids comprise a family of compounds with structures and mechanisms of action that resemble those of vitamin A (retinol), an essential nutrient which plays a role in cell growth and differentiation. The retinoids, which...

The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris.
January 1, 2005... Abstract Clindamycin phosphate is the most widely used topical antibacterial agent for acne treatment. Treatment of patients with mild to moderate acne vulgaris with a new foam formulation (clindamycin foam, CF) for 12 weeks was at least...

Innovative uses of imiquimod.
January 1, 2005... Abstract Imiquimod (Aldara,[TM] 3M Pharmaceuticals) is a potent stimulator of the innate and adaptive arms of the immune system through induction, synthesis, and release of cytokines and chemokines. An extensive review of clinical trials,...

A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution.
January 1, 2005... Abstract Background: Blue light sources have been shown to be effective in the treatment of mild to moderate inflammatory acne vulgaris lesions. Objective: We evaluated the safety and efficacy of a new blue light source in the...

Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial.
January 1, 2005... Abstract Several in vitro and in vivo studies have shown inhibitory effects of zinc sulfate (ZnSO4) on Leishmania parasites. The objective of this study was to compare the efficacy of intralesional injections of 2% ZnSO4 solution with...

Simultaneous acral nodular eruption and flagellate erythema caused by bleomycin.(CASE REPORTS)
January 1, 2005... Abstract A 29-year-old male with AIDS was treated with bleomycin and vincristine for visceral Kaposi's sarcoma. Three days later, he developed two distinct eruptions simultaneously. One eruption was characterized by tender, erythematous,...

Complete resolution of generalized lichen planus after treatment with thalidomide.(CASE REPORTS)
January 1, 2005... Abstract Thalidomide has gained an infamous history due to severe birth defects observed in patients who had taken the drug to control nausea during pregnancy. (1) The medication was withdrawn from the market because of its teratogenicity,...

Porokeratosis: a solitary oral lesion.(CASE REPORTS)
January 1, 2005... Abstract Classic porokeratosis is a rare skin disease occasionally involving the oral mucosa. It is characterized by the clinically and histologically distinctive cornoid lamella. This case represents a variant of Mibelli's classic...

Palisaded encapsulated neuroma--a classic presentation of a commonly misdiagnosed neural tumor.(CASE REPORTS)
January 1, 2005... Abstract We present a case report of a classical presentation of palisaded encapsulated neuroma (PEN) of the skin occurring on the nasolabial crease and a review of the literature. A young woman presented with a smooth lobulated papule on...

Multiple basal cell carcinomas in a young adult treated with imiquimod 5%: a case report and literature review.(CASE REPORTS)
January 1, 2005... Abstract We present a case of basal cell carcinoma that is unique in the literature with regard to the rare combination of age of onset and number of BCCs at initial presentation that was successfully treated with imiquimod 5%. The...

Iatrogenic contact dermatitis due to propylene glycol.(CASE REPORTS)
January 1, 2005... Introduction Iatrogenic allergic contact dermatitis to propylene glycol (PG) is an important factor to consider in recalcitrant dermatitis. PG is widely used as a vehicle in many different types of products, from personal care products, to...

Telemedicine legal update 2004: reimbursement, the doctor-patient relationship, teleconsultations, and the legal status of digital images.(FOCUS ON: INFORMATION TECHNOLOGY)
January 1, 2005... Abstract Telemedicine is the practice of medicine across distance via telecommunications and interactive video technology. Telemedicine is most widely deployed in the US Military, prisons, rural areas, and ships. This article reviews the...

Electronic prescribing: an update.(FOCUS ON: INFORMATION TECHNOLOGY)
January 1, 2005... Abstract Electronic prescribing has been gaining momentum with the passage of recent federal legislation. This article attempts to present the current status of e-prescribing. "Electronic communications between physicians and...

Online drug information for dermatology patients.(FOCUS ON: INFORMATION TECHNOLOGY)
January 1, 2005... Abstract Information about medications appropriate for dermatologists and patients with skin diseases is readily available on the Internet. Authoritative educational material is supplied by academic dermatologic associations and...

Washington Whispers.
January 1, 2005... We present a review of some of the more common fillers, some of which are not available in the United States and some that are available for off-label use. Over the past few years fillers in conjunction with Botox[R] and lasers have arguably...

Hylaform Plus filler approved for facial wrinkles and folds.(PIPELINE PREVIEWS)
January 1, 2005... The FDA has approved the large-particle hyaluronic acid-based dermal filler Hylaform Plus (Hylan-B gel) for the correction of moderate to severe facial wrinkles and folds. Hylaform Plus was developed and is manufactured by Genzyme Corporation....

FDA grants market approval for Captique injectable gel.(PIPELINE PREVIEWS)
January 1, 2005... Inamed Corporation and Genzyme Corporation announced FDA approval for Captique[TM] injectable gel. Captique is the newest hyaluronic acid filler approved for use in the US. It is indicated for the correction of moderate to severe facial...

Clindamycin foam 1% (Evoclin[R]) gains FDA approval for the treatment of acne vulgaris.(PIPELINE PREVIEWS)
January 1, 2005... Connetics Corporation announced FDA approval of Evoclin (formerly known as Actiza) clindamycin 1% foam for once-daily topical application in the treatment of acne vulgaris. Evoclin is Connetics' first product approval aimed toward the acne...

New laser system approved for endovenous treatment of varicose veins.(PIPELINE PREVIEWS)
January 1, 2005... A 1,320-nm laser system, CoolTouch CTEV, gained FDA approval for the treatment of reflux of the greater saphenous vein (GSV) associated with varicose veins and varicosities. The laser system is distributed by CoolTouch, Inc., in the United...

FDA plans for increased monitoring of Accutane.(PIPELINE PREVIEWS)
January 1, 2005... The U.S. Food and Drug Administration is strengthening required monitoring of isotretinoin (Accutane[R]) in further efforts to reduce the risks of fetal exposure and birth defects associated with women who become pregnant while taking the drug....

New drug application submitted for IV meropenem.(PIPELINE PREVIEWS)
January 1, 2005... AstraZeneca Pharmaceuticals has submitted a supplemental new drug application with the FDA for its intravenous antibiotic meropenem (Merrem IV) seeking a new indication for the treatment of complicated skin and skin structure infections. The...

FDA warns Remicade may be associated with increased risk of lymphoma.(PIPELINE PREVIEWS)
January 1, 2005... The U.S. Food and Drug Administration and Centocor are warning healthcare providers of an increased risk of lymphoma associated with the use of infliximab (Remicade[R]) in patients with rheumatoid arthritis (RA) and Crohn's disease, according...

Connetics submits New Drug Application for Velac.(PIPELINE PREVIEWS)
January 1, 2005... Connetics Corporation announced that the FDA has accepted for filing a New Drug Application for Velac, an investigational topical agent combining clindamycin 1% and tretinoin 0.025% in a gel formulation as a potential new treatment for acne...

FDA grants approval for new oral solution of Levaquin.(PIPELINE PREVIEWS)
January 1, 2005... Levaquin[R] (levofloxacin) is FDA approved for 9 indications including the treatment of complicated skin and skin structure infections at a dose of 750 mg once daily. The U.S. Food and Drug Administration (FDA) has approved a new, once daily...

Aventis announces approval of extended release Allegra-D (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg).(PIPELINE PREVIEWS)
January 1, 2005... A 24-hour extended-release tablet form of fexofenadine HCl (Allegra-D 180 mg) made by Aventis Pharmaceuticals, Inc., was approved by the FDA for the relief of symptoms associated with seasonal allergic rhinitis in adults and children aged 12...

Lidocaine and Epinephrine solution for iontophoretic induction of analgesia approved.(PIPELINE PREVIEWS)
January 1, 2005... Empi, Inc., has announced FDA approval of a Lidocaine HCl 2% and Epinephrine 1:100,000 solution for use with the company's Action Patch Iontophoresis System for the iontophoretic induction of local analgesia during superficial dermatologic...

New chip implant allows for emergency retrieval of medical information.(PIPELINE PREVIEWS)
January 1, 2005... A new computer chip (VeriChip) has been approved by the FDA for implantation under the skin. VeriChip is an inert, encapsulated microchip that is energized and transmits information when activated by a VeriChip reader. According to the...

Dual wavelength laser (VariLite) receives FDA clearance.(PIPELINE PREVIEWS)
January 1, 2005... The FDA approved a dual wavelength laser (VariLite, made by IRIDEX Corporation) for use in 19 dermatologic indications including vascular lesions, leg veins, benign pigmented lesions, cutaneous lesions, hair removal, and moderate inflammatory...

ZD1839 (iressa) for recurrent or metastatic squamous cell carcinoma of the skin.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by M.D. Anderson Cancer Center Patients will receive 250 mg ZD1839 daily by mouth (1 course = 4 weeks). Patients will receive 6 courses of treatment. A patient may continue to...

Tetracycline in preventing skin rash in patients who are receiving drugs such as gefitinib and cetuximab for cancer.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is not yet open for patient recruitment. Sponsored by North Central Cancer Treatment Group National Cancer Institute (NCI). Randomized clinical trial to study the effectiveness of tetracycline in preventing skin rash in...

Leptin to treat lipodystrophy.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with...

To study the use of humanized CD25 in preventing the relapse of psoriasis vulgaris.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by Protein Design Labs. This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse. Condition...

Monoclonal antibody treatment for systemic lupus erythematosus.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This study will examine the safety and effects of the monoclonal antibody MRA in patients with...

Phase II randomized bilateral comparison of topical targretin gel 1% in alopecia areata.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by M.D. Anderson Cancer Center Ligand Pharmaceuticals. The rationale for the use of bexarotene in alopecia areata comes from the drugs' immunomodulatory effects. It has been shown...

Radiation therapy in preventing metastatic cancer in patients who have diagnostic procedures to identify malignant mesothelioma.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by Cancer Research UK. Randomized phase III trial to determine the effectiveness of radiation therapy in preventing metastatic cancer in patients who have undergone diagnostic...

Campath-1H for treating adult T-cell leukemia.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Cancer Institute (NCI). This study will examine the safety and effectiveness of Campath-1H for treating patients with adult T-cell leukemia (ATL). ATL is caused by a...

Vaccine treatment in combination with IL-2 and treated lymphocytes for advanced melanoma.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Cancer Institute (NCI). This study will examine the effectiveness of treating advanced melanoma with special tumor-fighting cells taken from the patient's blood or...

Gene therapy and vaccine treatment to treat metastatic melanoma.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Cancer Institute (NCI). This study will examine the safety and effectiveness of gene therapy for creating special tumor-fighting cells to treat patients with metastatic...

Ultraviolet light therapy for systemic lupus erythematosus.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Center for Research Resources (NCRR) Louisiana State University. OBJECTIVE: Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus...

Anti-CD20 in systemic lupus erythematosus.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The purpose of this study is to determine the safety and effectiveness of rituximab (anti-CD20) in treating...

MDX-010 antibody, MDX-1379 melanoma vaccine, or MDX-010/MDX-1379 combination treatment for patients with melanoma.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by Medarex. The purpose of this study is to determine the safety and efficacy of MDX-010 (anti-CTLA4) in combination with MDX-1379 in patients with previously treated, unresectable...

Chemical and genetic effects of the experimental anti-cancer drugs in cheek cells in cancer patients.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Institute of Dental and Craniofacial Research (NIDCR). This study will examine the effects of certain investigational anti-cancer drugs on the genetic and protein...

Infliximab to treat non-infectious scleritis.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Eye Institute (NEI) This small, preliminary study will examine whether multiple infusions of infliximab (Remicade[R] (Registered Trademark)) can control inflammation in...

Peptide-sensitized lymphocytes plus melanoma peptide immunization followed by IL-2 to treat patients with melanoma.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Cancer Institute (NCI). This study will determine whether certain lymphocytes (white blood cells) taken from a melanoma patient's blood or tumor and grown in the...

Lymphocyte-depleting conditioning followed by infusion of engineered lymphocytes and vaccination to treat advanced melanoma.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Cancer Institute (NCI). This study will use genetically engineered lymphocytes (white blood cells) and an experimental vaccine to treat advanced melanoma....

Interferon beta in treating patients with metastatic cutaneous melanoma or ocular melanoma.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by Cleveland Clinic Cancer Center National Cancer Institute (NCI). Phase II trial to study the effectiveness of interferon beta in treating patients who have metastatic cutaneous...

Intravenous mepolizumab in subjects with hypereosinophilic syndromes (HES).(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by GlaxoSmithKline. Hypereosinophilic syndrome (HES) is a rare disease with broad clinical signs and symptoms which is diagnosed based on a persistent blood eosinophil count of...

Interleukin-7 and peptide vaccine to treat metastatic melanoma.(CLINICAL TRIAL REVIEW)
January 1, 2005... This study is currently recruiting patients. Sponsored by National Cancer Institute (NCI). This study will determine the side effects and safety of giving interleukin-7 (IL-7) together with two melanoma peptides, gp100 and MART-1, to...

Skin Cancer Foundation update.
January 1, 2005... The Skin Cancer Foundation is the only national and international organization devoted exclusively to malignancies of the skin. It conducts public and medical education programs and provides support for research and professional training to...